

# Soluble Antigen of *M. leprae* Coupled with Liposomes Elicits Both "Early" and "Late" Delayed Hypersensitivity Skin Reactions<sup>1</sup>

Utpal Sengupta, Sudhir Sinha, Gopal Ramu, Ravinder K. Lavania,  
and Chhitar M. Gupta<sup>2</sup>

Lepromin is a preparation of killed *Mycobacterium leprae* of human or armadillo origin, and it is used extensively for the assessment of delayed-type hypersensitivity (DTH) against *M. leprae*. After intradermal injection of lepromin, two types of skin DTH responses are seen in people who are sensitized: an "early" (Fernandez) reaction which peaks at 24–48 hr and a "late" (Mitsuda) reaction which peaks at 3–4 weeks<sup>(17)</sup>. The late lepromin reaction has shown a strong correlation with immunity to mycobacterial infections in both experimental animals<sup>(2)</sup> and humans<sup>(5)</sup>. However, the integrity of bacterial morphology in a lepromin preparation appears to be essential for the development of a late reaction. Ultrasonically disrupted lepromin or the soluble extract of *M. leprae* (leprosin) elicit only the early reaction<sup>(22, 23)</sup>. There are speculations that the soluble antigen(s) may also produce a late reaction, provided the antigen is presented in the same manner as that of intact *M. leprae*<sup>(17, 22)</sup>. To investigate this possibility, we have used soluble antigen(s) of *M. leprae*<sup>(23)</sup> coupled with liposome as a skin-test antigen, hoping that such a system would mimic the antigen presentation by intact bacilli.

## MATERIALS AND METHODS

All of the chemicals and reagents used in this study were of the highest purity available. Egg lecithin was prepared as described earlier<sup>(21)</sup>. Gangliosides were isolated from

buffalo brain using the known method<sup>(13)</sup>. Cholesterol was purchased from Centron Research Laboratory, Bombay, India, and crystallized three times from methanol. Sodium cyanoborohydride was from Sigma Chemical Company, St. Louis, Missouri, U.S.A. Sodium <sup>125</sup>I-iodide (carrier-free) was bought from Bhabha Atomic Research Centre, Trombay, India.

***M. leprae* soluble antigen(s).** Soluble antigen(s) of *M. leprae*, prepared by the described method<sup>(23)</sup>, was kindly provided by Dr. R. J. W. Rees, Clinical Research Centre, Harrow, U.K. Briefly, *M. leprae* purified from infected armadillo tissues<sup>(25)</sup> were ultrasonically disrupted before ultracentrifugation (105,000 × *g* × 30 min). The supernatant, termed "leprosin-A," was used after protein estimation<sup>(14)</sup>.

**<sup>125</sup>I-labeling of the soluble antigen(s).** Fifty μg protein of the soluble antigen(s) (in 50 μl) was labeled with <sup>125</sup>I using the "Iodogen" technique<sup>(7)</sup>. More than 95% of the radioactivity was incorporated in the protein peak recovered after Sephadex G-25 gel filtration.

**Preparation of liposomes.** Unilamellar liposomes were prepared from egg lecithin (45 μM), cholesterol (45 μM), and gangliosides (9 μM) in 2.0 ml borate-buffered saline (10 mM borate containing 60 mM NaCl, pH 8.4) by probe-type sonication and fractionated by ultracentrifugation, as described earlier<sup>(9)</sup>.

**Covalent coupling of liposomes with antigen(s).** The soluble protein of *M. leprae* was covalently coupled to the liposome surface according to the method of Heath, *et al.*<sup>(10)</sup>. Briefly, liposomes were oxidized with sodium periodate (2 hr, 25–30°C, dark). The excess reagent was removed by gel filtration, and the liposome fractions, after pooling together, were concentrated to about 1 ml (5–

<sup>1</sup> Received for publication on 29 July 1987; accepted for publication in revised form on 17 September 1987.

<sup>2</sup> U. Sengupta, Ph.D.; S. Sinha, M.Sc.; R. K. Lavania, M.D., Central JALMA Institute for Leprosy, Taj Ganj, Agra 282001, India. G. Ramu, M.D., Sacred Heart Hospital, Kumbakonam 612401, India. C. M. Gupta, Ph.D., Division of Membrane Biology, Central Drug Research Institute, Lucknow 226001, India.

THE TABLE. Early (48 hr) and late (3 weeks) skin reactions with different antigen preparations in borderline tuberculoid leprosy patients.

| Patient | Reaction | LA <sup>a</sup> | L <sup>b</sup> | L1 <sup>c</sup> | L2 <sup>c</sup> | L3 <sup>c</sup> | C <sup>d</sup> |
|---------|----------|-----------------|----------------|-----------------|-----------------|-----------------|----------------|
| 1       | Early    | 29 <sup>e</sup> | 28             | 30              | 28              | 28              | 0              |
|         | Late     | 0               | 10             | 12              | 10              | 10              | 0              |
| 2       | Early    | 20              | 25             | 32              | 26              | 27              | <5             |
|         | Late     | 0               | 7              | 9               | 9               | 7               | 0              |
| 3       | Early    | 28              | 22             | ND <sup>f</sup> | 46              | 32              | <5             |
|         | Late     | 0               | 0              | ND              | 0               | 0               | 0              |
| 4       | Early    | 0               | 0              | ND              | 13              | 15              | <5             |
|         | Late     | 0               | 6              | ND              | 9               | 0               | 0              |
| 5       | Early    | 23              | 18             | ND              | 27              | 30              | <5             |
|         | Late     | 0               | 0              | ND              | 0               | 0               | 0              |
| 6       | Early    | 12              | 12             | ND              | 15              | 13              | 0              |
|         | Late     | 0               | 0              | ND              | 0               | 0               | 0              |
| 7       | Early    | 15              | 12             | ND              | 14              | 12              | 0              |
|         | Late     | 0               | 5              | ND              | 8               | 5               | 0              |
| 8       | Early    | 26              | 24             | ND              | 23              | 27              | 0              |
|         | Late     | 0               | 12             | ND              | 10              | 6               | 0              |
| 9       | Early    | 30              | 22             | ND              | 20              | 19              | 0              |
|         | Late     | 0               | 5              | ND              | 10              | 10              | 0              |
| 10      | Early    | 18              | 16             | ND              | 16              | 14              | 0              |
|         | Late     | 0               | 5              | ND              | 7               | 6               | 0              |

<sup>a</sup> LA = leprosin-A (10 µg/ml).

<sup>b</sup> L = Dharmendra lepromin (10<sup>7</sup> bacilli/ml).

<sup>c</sup> L1-3 = liposomized leprosin-A at 40, 20, and 10 µg protein/ml.

<sup>d</sup> C = control liposomes.

<sup>e</sup> Indurations in mm.

<sup>f</sup> ND = not determined.

7 µM lipid), as described earlier (20). To it were added the unlabeled *M. leprae* antigen(s) (about 8 mg), <sup>125</sup>I-labeled antigen(s) (≈50,000 cpm), and sodium cyanoborohydride (2 M, 10 µl/ml). The mixture was incubated at 25–30°C for 14–16 hr. It was chromatographed on a Sepharose 6B column (1.4 × 35 cm) using phosphate-buffered saline (10 mM phosphate containing 150 M NaCl, pH 7.4; PBS) as the eluant. The liposomes were recovered in the void volume. Under these conditions, 18–20% (≈1.5 mg unlabeled protein or ≈10,000 cpm) of the protein initially added got cross-linked to the liposome surface. The liposome-rich fractions were pooled together, dialyzed against sterile PBS, and filtered through a Millipore membrane (0.2 µm). A preparation of control liposomes was also subjected to the above-mentioned antigen coupling steps, in the absence of antigen.

**Testing of antigen-coupled liposomes.** The antigen-coupled liposomes were diluted to

10, 20, and 40 µg protein/ml sterile PBS and used for skin testing. Simultaneously, control liposomes (free of antigen), Dharmendra lepromin (19), and leprosin-A (23) were also tested. All of the preparations were coded and tested by a clinician (GR) in a double-blind manner. Ten borderline tuberculoid (BT) and five lepromatous (LL) leprosy patients (18) attending the outpatient department and wards of Central JALMA Institute of Leprosy (CJIL), Agra, India, were selected for the study. The test preparations were injected intradermally (0.1 ml each) into the back of every patient. The diameters of the skin indurations (mean of two readings at right angles to each other) were recorded in millimeters with the help of a vernier scale at 48 hr and 21 days. An induration of 5 mm or more was regarded as positive in the case of the 48-hr (early) reaction and that of 4 mm or more was regarded as positive for the 21-day (late) reaction (11). Biopsy specimens representing the early (48 hr) and late (21 day) skin reactions to the liposome-coupled antigen were fixed in Zenker-formol saline, processed, and embedded in paraffin. Five-µm sections were stained with hematoxylin and eosin (H&E). The sections were examined by a pathologist without referring to the case notes to avoid personal bias.

## RESULTS

The Table depicts the skin reactions in 10 BT patients at 48 hr (early) and at 21 days (late) elicited by the different antigen preparations and controls. While leprosin-A (LA) elicited only the early reaction, Dharmendra lepromin (L) elicited early, late, or both early and late reactions. In two patients tested initially, all three concentrations of liposomized leprosin elicited strong reactions. In subsequent patients, the use of the highest concentration (L1) was omitted. In all of these patients, liposomized antigen elicited early and late skin reactions akin to those elicited by Dharmendra lepromin, except in one patient who was early-reaction negative with Dharmendra lepromin but positive with liposomized antigen. Control liposomes induced insignificant reactions at 48 hr in four patients.

The 48-hr skin reaction elicited by liposomized leprosin showed a histological pic-




FIG. 1. Photomicrograph of 48-hr reaction of a BT case showing lymphocyte and polymorphonuclear infiltration (H&E  $\times 1200$ ).




FIG. 2. Photomicrograph of 21-day reaction of a BT case showing lymphocytes, epithelioid cells, and giant cells in the infiltrate (H&E  $\times 1200$ ).

ture of DTH, with a predominant lymphocytic infiltration. Polymorphonuclear cells were present to a lesser extent (Fig. 1). The 21-day reaction to the liposomized antigen showed a histological picture resembling a tuberculoid granuloma with focal collections of epithelioid and giant cells (Fig. 2). None of the five LL patients showed any positive skin reaction to these antigens.

#### DISCUSSION

Several studies have shown that the immunogenicity of antigens is improved by incorporating them in liposomes<sup>(8)</sup>. It has also been demonstrated that this action of liposomes is further enhanced when antigen is covalently attached on their surface<sup>(24)</sup>. These observations prompted us to covalently couple soluble *M. leprae* antigen(s) (leprosin) to liposomes, and then to determine whether the liposome-coupled antigen(s) could elicit both the early and late skin DTH responses.

The results of this study support the working hypothesis that the presentation of eliciting antigen(s) in a specific orientation is required for the development of late re-

actions. In the method of Heath, *et al.*<sup>(10)</sup> which we used, protein molecules are covalently linked with the liposome surface due to a reaction between the amino groups of the proteins and the aldehyde groups of the ganglioside via the formation of Schiff's bases. In the present situation, it seems that such a linkage does not adversely affect the antigenicity of the attached proteins. Apparently the liposomes presented surface-bound protein antigens to the host cells in the specific manner of intact *M. leprae* and thus activated the lymphoid cell precursors which were responsible for the development of the late skin-test reaction.

The cells may not require the continued presence of the stimulus for the development of late reactions, since we know that liposomes are rapidly disintegrated *in vivo*<sup>(1)</sup>. For the same reason, the adjuvant effect of liposomes may not be operational in the development of the late reaction. Moreover, in a separate study, when the liposome-entrapped leprosin was used for skin testing of BT patients it did not produce the late reaction although the early reaction was elicited (data not shown). Both early and

late reactions to the liposome-coupled antigen showed histological pictures corresponding to the reactions elicited by integral lepromin (4).

The early reaction elicited by control liposomes in some of the cases is not significant, since an early reaction of <5 mm is not regarded as positive (11, 23).

On the basis of the present study, it is not possible to define the molecule(s) involved in the development of the DTH reactions. The decision to use whole (unfractionated) soluble antigen was made because studies so far have led to diverse conclusions regarding the physicochemical properties of the DTH-eliciting antigens of *M. leprae* or even any other mycobacterium (3). Moreover, studies on *M. leprae* are limited due to non-availability of the organisms in sufficient quantities. The major source of *M. leprae* remains the experimentally infected nine-banded armadillo (12). Recently, isolation of molecularly defined *M. leprae* antigens has been made possible with the help of monoclonal antibodies (6) and gene cloning (26). Such preparations would be those of choice for future work using liposomes.

There is experimental evidence to suggest that the late (21 day) DTH reaction is a marker for protective immunity against multibacillary mycobacterial infections (2, 5). Since the *M. leprae* antigen covalently linked with liposomes is capable of eliciting the late reaction, liposome may serve as a carrier and immunopotentiator of activity of molecularly defined, cell-mediated immunity-inducing antigens of *M. leprae* which are presently being evolved (14, 15).

#### SUMMARY

The soluble antigen(s) of *Mycobacterium leprae* was(were) coupled to liposomes and used for skin testing of leprosy patients, hoping that this mode of antigen presentation would be identical to that of integral lepromin. The liposomized antigen(s) elicited both early (24–48 hr) and late (3–4 weeks) delayed-type hypersensitivity reactions, true to the nature of lepromin, unlike the soluble antigen(s) alone which elicit(s) only the early reaction.

#### RESUMEN

Se incorporaron antígenos solubles de *Mycobacterium leprae* a liposomas y se usaron para pruebas en

piel en pacientes con lepra esperando que este modo de presentación del antígeno pudiera ser idéntico al de la lepromina integral. Los antígenos incluidos en los liposomas, indujeron tanto las reacciones de hipersensibilidad retardada tempranas (24–48 h) como las tardías (3–4 semanas), en tanto que los antígenos solubles solos nada más indujeron la reacción temprana.

#### RÉSUMÉ

On a couplé l'antigène ou les antigènes de *Mycobacterium leprae* à des liposomes pour pratiquer des épreuves cutanées chez des malades de la lèpre, dans l'espoir de démontrer que ce mode de présentation antigénique serait identique à celui de la lepromine intégrale. L'antigène ou les antigènes ont entraîné des réactions précoces après 24 à 48 heures, et des réactions tardives du type d'hypersensibilité retardée après 3 et 4 semaines, comme c'est le cas après injection de lepromine, alors que l'antigène ou les antigènes solubles administrés seuls n'ont entraîné qu'une réaction précoce.

**Acknowledgments.** We are grateful to Dr. (Ms.) A. Bali, National Institutes of Health, Bethesda, Maryland, U.S.A., for helping in the standardization of techniques. We are also grateful to Dr. K. V. Desikan, CJIL, Agra, India, for his critical review of the manuscript. Mr. Anil Chopra provided secretarial assistance and Mr. H. O. Agarwal provided the photomicrographs. Part of the work was supported by ad hoc grants from the Indian Council of Medical Research (vide scheme 1/8/82).

#### REFERENCES

- BALI, A., DHAWAN, S. and GUPTA, C. M. Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component. *FEBS Lett.* **154** (1983) 373–377.
- CURTIS, J. and TURK, J. L. Mitsuda-type lepromin reaction as a measure of host resistance in *Mycobacterium lepraemurium* infection. *Infect. Immun.* **24** (1979) 492–500.
- DANIEL, T. M. and JANICKI, W. Mycobacterial antigens: a review of their isolation, chemistry and immunological properties. *Microbiol. Rev.* **42** (1978) 84–113.
- DESIKAN, K. V., MUKHERJEE, A., RAMU, G. and TIWARI, V. D. Sequential histological study of lepromin reaction. *Int. J. Lepr.* **51** (1983) 473–480.
- DHARMENDRA and CHATTERJEE, K. R. Prognostic value of the lepromin test in contacts of leprosy cases. *Lepr. India* **27** (1955) 149–153.
- ENGERS, H. D. Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. *Infect. Immun.* **48** (1985) 603–605.
- FRAKER, P. J. and SPECK, J. C. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro 3 $\alpha$ , 6 $\alpha$ -diphenyl-

- glycoluril. *Biochem. Biophys. Res. Commun.* **80** (1978) 849–857.
8. GREGORIADIS, G. Liposomes for drugs and vaccines. *Trends Biotechnol.* **3** (1985) 235–241.
  9. GUPTA, C. M. and BALI, A. Carbamyl analogs of phosphatidylcholines: synthesis, interaction with phospholipases and permeability behavior of their liposomes. *Biochim. Biophys. Acta* **663** (1981) 506–515.
  10. HEATH, T. D., MACHER, B. A. and PAPAHD-JOPOULOS, D. Covalent attachment of immunoglobulins to liposomes via glycosphingolipids. *Biochim. Biophys. Acta* **640** (1981) 66–81.
  11. JOPLING, W. H. The lepromin test. In: *Handbook of Leprosy*. 3rd ed. London: Heineman Medical Books Ltd., 1984, pp. 47–50.
  12. KIRCHHEIMER, W. F. and STORRS, E. E. Attempts to establish the armadillo (*Dasypus novemcinctus* Linn) as a model for the study of leprosy. *Int. J. Lepr.* **39** (1971) 692–702.
  13. LAINE, R. A., STELLNER, K. and HAKOMORI, S. I. Isolation and characterisation of membrane glycosphingolipids. *Methods Membrane Biol.* **2** (1974) 214–244.
  14. LOWRY, O. H., ROSEBROUGH, N. J. and RANDALL, R. J. Protein measurement with Folin phenol reagent. *J. Biol. Chem.* **193** (1951) 265–275.
  15. MUSTAFA, A. S., GILL, H. K., NERLAND, A., BRITTON, W. J., MEHRA, V., BLOOM, B. R., YOUNG, R. A. and GODAL, T. Human T cell clones recognize a major *M. leprae* protein antigen expressed in *E. coli*. *Nature* **319** (1986) 63–66.
  16. OTTENHOFF, T. H. M., KLAFTER, P. R., IVANYI, J., ELFERINK, D. G., DE WIT, M. Y. L. and DE VRIES, R. R. P. *M. leprae*-specific protein antigens defined by cloned human helper T cells. *Nature* **319** (1986) 66–68.
  17. REES, R. J. W. The significance of the lepromin reaction in man. *Progr. Allergy* **8** (1964) 224–258.
  18. RIDLEY, D. S. and JOPLING, W. H. Classification of leprosy according to immunity; a five-group system. *Int. J. Lepr.* **34** (1966) 255–273.
  19. SENGUPTA, U., RAMU, G. and DESIKAN, K. V. Assessment of Dharmendra antigen. II. Standardization of the antigen. *Lepr. India* **51** (1979) 316–322.
  20. SINGHAL, A., BALI, A. and GUPTA, C. M. Antibody-mediated targeting of liposomes to erythrocytes in whole blood. *Biochim. Biophys. Acta* **880** (1986) 72–77.
  21. SINGLETON, M. B., GRAY, M. S., BROWN, M. L. and WHITE, J. L. Chromatographically homogeneous lecithin from egg phospholipids. *J. Am. Oil Chem. Soc.* **42** (1965) 53–56.
  22. SINHA, S., SENGUPTA, U., RAMU, G. and DESIKAN, K. V. Assessment of Dharmendra antigen. III. Comparative study with Mitsuda antigen. *Lepr. India* **51** (1979) 323–329.
  23. SMELT, A. H. M., REES, R. J. W. and LIEW, F. Y. Induction of delayed type hypersensitivity to *M. leprae* in healthy individuals. *Clin. Exp. Immunol.* **44** (1981) 501–506.
  24. SNYDER, S. L. and VANNIER, W. E. Immunologic response to protein immobilized on the surface of liposomes via covalent azo-bonding. *Biochim. Biophys. Acta* **772** (1984) 288–294.
  25. WORLD HEALTH ORGANIZATION. Report of the Enlarged Steering Committee Meeting of IMMLEP. Protocol 1/79: WHO, 1979, annex 1, p. 4.
  26. YOUNG, R. A., MEHRA, V., SWEETSER, D., BUCHANAN, T., CLARK-CURTISS, J., DAVIS, R. W. and BLOOM, B. R. Genes for the major protein antigens of the leprosy parasite *Mycobacterium leprae*. *Nature* **316** (1985) 450–452.